Navigation Links
Oramed CEO to be Panelist at BIO International Convention Breakout Session on Israel Becoming Biotech Leader
Date:4/22/2013

ooking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission
'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oramed Pharmaceuticals Moves Forward with Investigational New Drug Application for Oral Insulin
2. Bioassociate Announces Initiation of Coverage on Oramed Pharmaceuticals, Inc.
3. Oramed Pharmaceuticals Announces Reverse Stock Split
4. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
5. Trigemina to Present at the 2013 BIO International Convention
6. Infinata’s BioPharm Insight to Offer Exclusive Preview of 2013 Key Reports at the BIO International Conference and Partnerships in Clinical Trials
7. Campbell Alliance to Release New Forward-Looking Industry Report on Deal-Making Trends at the 2013 BIO International Convention
8. 20 Swiss Biotech Firms and Organizations will Populate the Swiss Pavilion at BIO 2013 International Convention
9. Blood-Based Circulating Microvesicles (cMV) Data to be Presented at the 2013 International Society for Extracellular Vesicles (ISEV)
10. Dyadic International To Speak At Advanced Biofuels Leadership Conference Panel Discussion
11. Janssen Announces Data from Simeprevir in Hepatitis C Patients Will Be Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Telomere Biosciences, LLC (Telomere Biosciences) ... for Dogs" with Telomerase Activation Complex , ... world for dogs. Telomeres are the protective caps ... body. A wealth of ground-breaking research by some ... and Aging, including Nobel laureates, has demonstrated a ...
(Date:8/21/2014)... , Aug. 21, 2014 ... Immune Pharmaceuticals Inc., a biotechnology company, on its ... Immune previously traded on OTCQX®, the best marketplace ... OTC Markets Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... on the successful execution of its growth strategy ...
(Date:8/21/2014)... Ontotext S4 , The Self Service Semantic ... Now the same enterprise hardened text mining, Linked Data ... is available to start-ups and mid-size businesses at a ... do not have resources to evaluate and prototype enterprise ... there is no need for on premise hardware provisioning ...
(Date:8/20/2014)... RALEIGH, N.C. , Aug. 20, 2014 /PRNewswire/ ... clinical research services located in Raleigh, ... Bradford Evans as Vice President of ... Administration, Brad will oversee all corporate processes, including ... to joining Clintrax Global, Brad worked as an ...
Breaking Biology Technology:Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4Clintrax Global, Inc. Announces Addition to Executive Team 2
... 11, 2008 RiverVest Venture Partners,announced today that ... Venture Fund II, L.P., with total committed capital ... which was licensed,as a Small Business Investment Company, ... tier of leverage from the Small Business Administration., ...
... CAMBRIDGE, Mass., April 11 Biopure,Corporation (Nasdaq: ... United Kingdom,s,Medicines and Healthcare products Regulatory Agency ... to be in general compliance,with the principles ... in the Commission Directives. The company received ...
... Renowned Clinic Invests in Extracranial Radiosurgery, SUNNYVALE, ... ), a global leader in the field of ... part of the renowned,Hirslanden group of private hospitals, ... System sold in Switzerland, allowing patients greater,access to ...
Cached Biology Technology:RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner 2RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner 3Biopure Operations Compliant With U.K. Manufacturing Guidelines 2Biopure Operations Compliant With U.K. Manufacturing Guidelines 3First CyberKnife System Sold in Switzerland 2First CyberKnife System Sold in Switzerland 3First CyberKnife System Sold in Switzerland 4
(Date:8/21/2014)... pancreas digesting itself resulting in severe abdominal pain, vomiting ... 20,000 patients are diagnosed with the disease resulting in ... is restricted to intravenous fluid and nutritional support. ... Sciences, who led the research, said "The major causes ... and excessive alcohol intake combined with a high fat ...
(Date:8/20/2014)... SALT LAKE CITY Researchers at Huntsman Cancer Institute (HCI) ... mutated forms of the gene that encodes BCR-ABL, the ... (CML). According to the American Cancer Society, nearly 6,000 ... , Drugs already in use, called tyrosine kinase inhibitors ... disease. They do not cure CML but control it ...
(Date:8/20/2014)... State University, the Wellcome Trust Sanger Institute and the ... Mycobacterium pinnipedii from skeletons found in Peru ... is a relative of the TB bacterium that affects ... These researchers assume that seals carried the pathogens from ... lions was unexpected" comments Sebastien Gagneux, from the Swiss ...
Breaking Biology News(10 mins):Insulin offers new hope for the treatment of acute pancreatitis 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... heart having limited ability to regenerate following injury, heart disease ... developed world. Research impacting strategies for heart repair will be ... Houston (UH). Eric N. Olson, a molecular biologist ... "Heart Making and Heart Breaking: New Strategies for Heart Repair." ...
... Tampa, Fla. (May. 8, 2012) Two studies appearing ... (20:11-12), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/ , ... that may make them therapeutically useful and appropriate for ... immature dental pulp stem cells , A ...
... Angeles, CA (May 8, 2012) A new study from ... when men chair committees that select scientific awards recipients, males ... new study also reports that while in the past two ... scientific achievements, compared to men, they win more service and ...
Cached Biology News:New heart repair strategies discussed at UH lecture May 15 22 Cell Transplantation studies impact dental stem cell research for therapeutic purposes 22 Cell Transplantation studies impact dental stem cell research for therapeutic purposes 3Women's scientific achievements often overlooked and undervalued 2
GRADIENT MAKER, 30 ML, 1 EA. Category: Protein Vertical Instruments....
Recombinant Rat Leptin, CF...
actin from rabbit muscle Cell Biology Cytoskeletal Probes Actin and Actin Probes...
...
Biology Products: